Durability of CAR T-cell therapy response may depend on pretreatment disease burden in leukemia patients
Although most patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) experienced complete response after treatment with a type of CAR T-cell immunotherapy, pretreatment disease burden impacted the durability of ...
Apr 4, 2017